ORNBV Orion Oyj Class B

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

ORION CORPORATION

PRESS RELEASE

28 JANUARY 2025 at 09.00 EET

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

Orion will publish its Financial Statement Release for 2024 on Tuesday, 25 February 2025 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at  after publishing.

Webcast and conference call

A webcast and conference call for analysts, investors and media representatives will be held on Tuesday, 25 February 2025 at 13.30 EET.

A link to the live webcast is available on Orion's website at . A recording of the event will be made available on the website later on the same day.

To join the conference call, please register through the following link:

The phone numbers and the conference ID required to access the conference will be provided after the registration. If you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be sent via the chat function of the webcast.

                                                

Contact person:

Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
28/01/2025

Underlying

ORNBVOrion Oyj Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Darolutamide receives EU approval in third indication for patients wit...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST           Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use darolutamide plus ADT, wi...

July 21, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle...

Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa ORION OYJLEHDISTÖTIEDOTE 21.7.2025 klo 10.30          Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Euroopan komissio on myöntänyt darolutamidille myyntiluvan levinneen hormonisensitiivisen eturauhassyövän (mHSPC) hoitoon yhdessä tavanomaiseen hormonaalisen hoidon (androgeenideprivaatioterapia eli ADT-hoito) kanssa. Päätös perustuu satunnaistetun (vaiheen III) ARANOTE-tutkimuk...

July 21, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion Group Half-Year Financial Report January–June 2025

Orion Group Half-Year Financial Report January–June 2025 ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2025 18 JULY 2025 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2025 April–June 2025 Highlights Net sales totalled EUR 416.5 (April–June 2024: 328.2) million Operating profit was EUR 104.6 (65.8) millionBasic earnings per share were EUR 0.59 (0.37)Cash flow from operating activities per share was EUR 0.57 (0.20)Outlook for 2025 was upgraded in July: Net sales are estimated to be EUR 1,630 million to EUR 1,730 million. Operating profit is estimated to be EUR 400 m...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025 ORION OYJ PUOLIVUOSIKATSAUS 1–6/2025 18.7.2025 klo 12:00 Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025 Huhti–kesäkuu 2025 lyhyesti Liikevaihto oli 416,5 miljoonaa euroa (328,2 miljoonaa euroa 4–6/2025)Liikevoitto oli 104,6 (65,8) miljoonaa euroaLaimentamaton osakekohtainen tulos oli 0,59 (0,37) euroaOsakekohtainen liiketoiminnan rahavirta oli 0,57 (0,20) euroaNäkymäarvio vuodelle 2025 päivitettiin heinäkuussa. Liikevaihdon arvioidaan olevan 1 630–1 730 miljoonaa euroa. Liikevoiton arvioidaan olevan 400–500 miljoonaa euroa. Tam...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion Corporation’s financial reporting and Annual General Meeting in ...

Orion Corporation’s financial reporting and Annual General Meeting in 2026 ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 18 JULY 2025 at 9.30 EEST         Orion Corporation’s financial reporting and Annual General Meeting in 2026 Orion Corporation will publish its Financial Statement Release 2025 on Thursday, 12 February 2026. The publication dates of the Interim Reports and the Half-Year Financial Report in 2026 are as follows: Interim Report January-March 2026 Thursday 23 April 2026 Half-Year Financial Report January-June 2026 Friday 17 July 2026 Interim Report Ja...

July 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch